INTRODUCTION
score), Quality of Life (DLQI) and details of the drug treatment were recorded in predefined Case Record Form (CRF). Based on prescribed treatment by dermatologist, patients were Grouped as: Group A (n=29): {corticosteroid group [inj. dexamethasone 4 to 6 mg once a day intravenously followed by tab prednisolone 20 to 40 mg once a day and maintained by 10 to 20 mg of prednisolone once a day]}, Group B (n=30): {corticosteroid [inj. dexamethasone 4 to 6 mg once a day intravenously followed by tab prednisolone 20 to 40 mg once a day and maintained by 10 to 20 mg of prednisolone once a day] plus azathioprine [50 mg twice daily] group} and Group C (n=25): {corticosteroid [inj. dexamethasone 4 to 6 mg once a day intravenously followed by tab prednisolone 20 mg once a day and maintained by 5 to 20 mg of prednisolone once a day] plus rituximab [1 gm Injection 2 times at 15 days interval (Total 2 injections)]}. All study treatments were allocated to patients by government supply and treatment selection was based on decision of dermatologist. All patients were followed at 2 (1 st follow up), 6 (2 nd follow-up) and 12 weeks (3 rd follow up). Disease severity was assessed by Kumar's score 11 and Quality of Life was assessed by Dermatology Life Quality Index (DLQI). 12 At each follow up visit, presenting complaints, any change in drug treatment, Kumar's score and quality of life was recorded and analyzed at the end of the study. Details of the adverse drug reaction (ADR) if any, was recorded in the CRF. Analysis of cost of drug incurred was calculated for given treatment from time of enrollment to 3 rd follow up visit. 
RESULTS
Total 84 patients were included in the study according to inclusion and exclusion criteria. Patients were followed up at the 2 weeks (1 st follow up), 6 weeks (2 nd follow up) and 12 weeks (3 rd follow up) of treatment.
As shown in Table 1 , the mean age of total number of patients was 45.42 ± 1.58 years, 33 (39.28%) male and 51 (60.72%) were female patients with higher female to male ratio. (Table 1) Mean of baseline Kumar's score was comparable between all groups [4.31 ± 0.14 (group A), 4.70 ± 0.13 (group B) and 4.68 ± 0.22 (group C)]. There was significant reduction (p<0.001) in oral and skin score and total Kumar's score and at 2 nd and 3 rd follow-up as compared to baseline and 1 st follow up and at 3 rd follow up as compared to 2 nd follow up in all treatment groups. At 3 rd follow up, there was significant (p<0.01) reduction in Kumar's score in group C as compared to group A and group B. (Figure 1 ) Mean difference of Kumar's score between baseline and 3 rd follow up data was significantly higher in group C as compared to group A (p<0.01) and group B (p<0.05). (Table 2 ) Total 3 patients (10.34%) in group A, 4 patients (13.33%) in group B and 12 patients (48%) in group C achieved complete reduction in Kumar's score at 3 rd follow up (12 weeks). (Table 3 Our study shows corticosteroid alone or in combination with azathioprine or rituximab significantly (p<0.001) decrease severity of disease by reducing both oral and skin site of Kumar's score at 2 nd and 3 rd follow-up i.e. 6 and 12 weeks respectively. Similar results were observed in different studies with corticosteroid alone, 17 corticosteroid plus azathioprine 18 and corticosteroid plus rituximab 19 treatment in Pemphigus vulgaris. Corticosteroid decreases inflammation by suppressive effects on cytokines and other mediators of inflammation. 20 In addition, azathioprine plus corticosteroid combination decreases the proliferation by inhibiting synthesis of purines and impaired the lymphocyte function after 4-8 weeks. 21 Rituximab decreases the precursor of autoantibody producing plasma cells and marked decrease in anti-desmoglein-3 antibodies within 4-6 weeks. 22 Thus disease severity is reduced by corticosteroid alone or in combination with azathioprine or rituximab. At the end of 12 weeks, we observed that, there was significant (p<0.01) reduction in both oral and skin site Kumar's score in group C as compared to group A and group B. Mean difference (Baseline to 3 rd follow up) of Kumar's score was also significantly higher in group C as compared to group A (p<0.01) and group B (p<0.05). This suggest better efficacy of corticosteroid plus rituximab therapy as compared to corticosteroid alone and corticosteroid plus azathioprine therapy. In our study, nearly half of the patients in group C achieved complete remission of disease at 3 rd follow-up which was higher as compared to group A (10%) and group B (13 %). Kanwar study (2012) reported 40% complete remission where rituximab 375 mg/m 2 was given once weekly QOL at 3 rd follow up:
Mean score of each parameter of QOL significantly (p<0.001) reduced at 3 rd follow up as compared to baseline and 1 st follow up in all treatment group. Significant (p<0.001) reduction in symptoms and feeling parameter of QOL at 3 rd follow up as compared to 2 nd follow up and significant (p<0.01) reduction in work and school parameter of QOL at 3 rd follow up as compared to 2 nd follow up was seen in group A. In group B, significant (p<0.001) reduction in symptoms and feeling, work and school and personal relationship parameter of QOL at 3 rd follow up as compared to 2 nd follow up and significant (p<0.01) reduction in daily activities and treatment parameter of QOL at 3 rd follow up as compared to 2 nd follow up was observed. In group C, significant (p<0.001) reduction was seen in symptoms and feeling and treatment parameter of QOL at 3 rd follow up as compared to 2 nd follow up and also significant (p<0.05) reduction in work and school parameter of QOL at 3 rd follow up as compared to 2 nd follow up.
Mean difference of DLQI score was significantly higher in group C as compared to group A (p<0.001) and group B (p<0.05). Mean difference of symptoms and feelings parameter at 3 rd follow up was significantly higher in group C as compared to group A (p<0.01). (Table 2) Correlation between Kumar's Score and Quality of Life Correlation between Kumar's score and QOL was carried out using Pearson parametric correlation test. Weak positive correlation in group A (0.39) and B (0.49) and strong positive correlation in group C (0.58) was observed. (Figure 3 ) Significant correlation was seen in group C (p<0.05).
Adverse drug reaction
Out of 52 adverse drug reaction, 20 (38.46%), 19 (36.53%) and 13 (25%) ADRs were reported in in group A, B and C respectively. All ADRs were reported to regional ADR monitoring center of Pharmacovigilance Programme of India (PvPI). All ADRs were assessed as possible except weight gain, infection and vomiting which were assessed as probable by using WHO-UMC causality assessment score. All ADRs were assesses as not preventable by using modified Schumock and Thornton scale. (Table 3) 13 Mean cost of drug incurred per patient was 1787.66 ≠, 2620.84 ≠ and 51,371.40 ≠ in group A, B and C respectively. It was observed that the total and individual cost of drug incurred was significantly (p<0.001) higher in group C as compared to group A and B. (Table 3) 
DISCUSSION
In the present study, efficacy of drugs and QOL in newly diagnosed patients suffering from Pemphigus vulgaris were studied. In our study, we observed higher number of female patients suffering from Pemphigus vulgaris (60.72%). Corticosteroid alone/in combination with azathioprine/or in combination with rituximab significantly (p<0.001) reduced disease severity (Kumar's score) and improve QOL (DLQI) at 2 nd (6 weeks) and 3 rd follow-up (12 weeks) as compared to baseline and 1 st follow-up (2 weeks). We observed that nearly half of the patients in group C achieved complete remission (complete reduction in Kumar's score) at 3 rd follow-up (12 weeks) which was higher as compared to group A (10%) and group B (13 %). Patients treated with corticosteroid plus rituximab therapy developed less ADRs (25%) than corticosteroid alone (38.46%) and corticosteroid with azathioprine treated group (36.53%). In our study, 60.72 % were female patients followed by labourers (22.61%) and farmers (15.47%). Estrogen (increases immunity, autoantibody production) 14 may be contributing factor for higher number of female patients (particularly housewives) in our study. 15 Sun exposure can worsen combination with azathioprine therapy. We have evaluated efficacy and QOL over a period of time and done correlation between efficacy and QOL. Due to chronic nature of disease, longer study duration with large sample size will help to better analysis of correlation between efficacy and QOL.
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for 4 weeks. 23 In our study, 1 gm of rituximab dose was prescribed for 2 times at 15 days interval. This could be the contributing factor for higher rate of complete remission in our study. Corticosteroid alone, corticosteroid plus azathioprine and corticosteroid plus rituximab therapy improves QOL by reducing score of each parameter and total DLQI score after 6 and 12 weeks of treatment. This suggests reduction in disease severity over a period of 12 weeks and hence patients feel better, taking interest in daily activities, able to participate in social activities (including improvement in relation with family members and friends) and improvement in work output at working place. At the end of 12 weeks, we observed that, there was significant (p<0.01) reduction in DLQI score in group C as compared to group A and group B. Mean difference (Baseline to 3 rd follow up) of DLQI score was significantly higher in group C as compared to group A (p<0.001) and group B (p<0.05). Analysis of each parameter of QOL between treatment groups suggest that there was significant improvement in symptoms and feeling parameters in corticosteroid plus rituximab group than corticosteroid alone patients. Intergroup comparison suggest that there was significant improvement in QOL in patients treated with corticosteroid plus rituximab therapy as compared to corticosteroid alone and corticosteroid plus azathioprine therapy. Positive correlation between Kumar's score and DLQI score was seen in all groups which suggest that when Kumar's score decreases (decrease in disease severity), the DLQI score also decreases (improvement in QOL). All groups were associated with positive correlation between efficacy and QOL indicating decrease in disease severity associated with improvement in QOL. The correlation between Kumar's score and QOL was significant in treatment group C (p<0.05) as compared to group A and B which suggests patients treated with corticosteroid plus rituximab lead to more improvement in QOL than corticosteroid alone and corticosteroid plus azathioprine therapy. Complete remission in disease severity in corticosteroid plus rituximab group can lead to better correlation between efficacy and QOL. Decrease in inflammation and inflammatory cytokines (corticosteroid), inhibition of synthesis of purines, impairment in lymphocyte function (corticosteroid plus azathioprine), reduction in autoantibodies (dsg-1 and -3) and depletion of B cell (corticosteroid plus rituximab) can lead to decrease in disease severity and hence improve QOL. In corticosteroid plus rituximab group, better reduction in disease severity and improvement in QOL was observed as compared to corticosteroid alone/plus azathioprine group (prednisolone-10-20 mg). In addition, maintenance dose of prednisolone requirement is less (5-10 mg) in corticosteroid plus rituximab group which may contribute to less ADR particularly ADR due to corticosteroid. In our study, patients developed pedal edema, fever, acne, oral candidiasis, urinary tract infection, weight gain, hyperglycemia, infection, pneumonia, diabetes mellitus and hypertension who administered dexamethasone or prednisolone. In a study carried out by Lihite et al., (2016) it was reported that the patient treated with corticosteroid therapy also developed ADRs such as oral candidiasis, pulmonary edema, hyperglycemia, secondary infections, electrolytes imbalance, gastritis, lung abscess, psychosis, and septicaemia. 24 Major disadvantage with rituximab is higher cost as rituximab is too expensive.
CONCLUSION
Our study concludes, all treatment groups are efficacious for the treatment of Pemphigus vulgaris. Corticosteroid alone and corticosteroid plus azathioprine having similar efficacy for treatment and improvement of the QOL in patients suffering from pemphigus vulgaris. Corticosteroid plus rituximab combination therapy is more efficacious, can cause complete remission and associated with significant improvement of QOL with less ADRs but too expensive than corticosteroid alone or in
